Mantle cell lymphoma : clinical characteristics, prevalence and treatment options [E-Book]
Series: Cancer etiology, diagnosis, and treatmentsPublisher: New York : Nova Biomedical, [2015]Description: 1 online resourceContent type:- text
- computer
- online resource
- 9781634823838
- 1634823834
Contents:
Summary: Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin's Lymphoma (NHL) with varying clinical presentations, ranging from indolent disease to highly aggressive symptoms. MCL represents approximately 3-10% of non-Hodgkin lymphomas, and has increased in incidence over the past several decades. The majority of patients respond to initial therapy, but remission duration is typically short. This book discusses the clinical characteristics of mantle cell lymphoma, as well as its prevalence and examines several treatment options available.
Chapter 1: Diagnosis, Prognosis and Genetic Features of Mantle Cell Lymphoma -- Epidemiology and Clinical Features -- Morphologic and Immunophenotypic Features -- Mantle Cell Lymphoma In Situ -- Differential Diagnosis -- Genetic and Molecular Features -- Prognostic Factors.
Chapter 2: Mantle Cell Lymphoma: Current Treatment Strategies in the Era of Targeted Agents -- Prognostic Indicators for MCL -- Cellular Pathways and Potential Targets for Therapy -- Treatment of Mantle Cell Lymphoma -- First Line therapy -- First Line Consolidation Therapy -- Post Induction Maintenance Therapy -- Salvage Therapy for Relapsed or Refractory MCL -- Novel Agents in Treatment of MCL -- Chapter 3: Targeted Drugs in the Treatment of Mantle Cell Lymphoma.
Upfront Treatment -- Targeted Treatment in Resistant/Relapsed MCL Patients -- Chapter 4: Emerging Role of Novel Agents in the treatment of Mantle Cell Lymphoma -- Immunomodulatory Agents in MCL --The Role of BTK Inhibitors in MCL -- mTOR Inhibitors in MCL -- MCL and PI3K Inhibitors -- Cyclin-D1 Inhibitors in MCL -- Chapter 5: Current Place of Proteasome Inhibitors in the Treatment of Mantle Cell Lymphoma -- The Molecular Basis of Proteasome Inhibition in MCL,
Bortezomib in Newly Diagnosed MCL -- Bortezomib in Relapsed/Refractory MCL -- Other Bortezomib -- Containing Combinations in MCL -- Newer Proteasome Inhibitors in MCL -- Proteasome Inhibitors in Combination with Novel Targeted Therapies in MCL -- Index""
| Item type | Home library | Class number | URL | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|
| Electronic book | Stenhouse Library (Kingston Hospital) Online | Link to resource | Available |
Includes bibliographical references and index.
Description based on print version record and CIP data provided by publisher.
Chapter 1: Diagnosis, Prognosis and Genetic Features of Mantle Cell Lymphoma -- Epidemiology and Clinical Features -- Morphologic and Immunophenotypic Features -- Mantle Cell Lymphoma In Situ -- Differential Diagnosis -- Genetic and Molecular Features -- Prognostic Factors.
Chapter 2: Mantle Cell Lymphoma: Current Treatment Strategies in the Era of Targeted Agents -- Prognostic Indicators for MCL -- Cellular Pathways and Potential Targets for Therapy -- Treatment of Mantle Cell Lymphoma -- First Line therapy -- First Line Consolidation Therapy -- Post Induction Maintenance Therapy -- Salvage Therapy for Relapsed or Refractory MCL -- Novel Agents in Treatment of MCL -- Chapter 3: Targeted Drugs in the Treatment of Mantle Cell Lymphoma.
Upfront Treatment -- Targeted Treatment in Resistant/Relapsed MCL Patients -- Chapter 4: Emerging Role of Novel Agents in the treatment of Mantle Cell Lymphoma -- Immunomodulatory Agents in MCL --The Role of BTK Inhibitors in MCL -- mTOR Inhibitors in MCL -- MCL and PI3K Inhibitors -- Cyclin-D1 Inhibitors in MCL -- Chapter 5: Current Place of Proteasome Inhibitors in the Treatment of Mantle Cell Lymphoma -- The Molecular Basis of Proteasome Inhibition in MCL,
Bortezomib in Newly Diagnosed MCL -- Bortezomib in Relapsed/Refractory MCL -- Other Bortezomib -- Containing Combinations in MCL -- Newer Proteasome Inhibitors in MCL -- Proteasome Inhibitors in Combination with Novel Targeted Therapies in MCL -- Index""
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin's Lymphoma (NHL) with varying clinical presentations, ranging from indolent disease to highly aggressive symptoms. MCL represents approximately 3-10% of non-Hodgkin lymphomas, and has increased in incidence over the past several decades. The majority of patients respond to initial therapy, but remission duration is typically short. This book discusses the clinical characteristics of mantle cell lymphoma, as well as its prevalence and examines several treatment options available.
Master record variable field(s) change: 050, 082, 650
There are no comments on this title.
Log in to your account to post a comment.
London Health Libraries Consortium Privacy notice and Membership terms and conditions